Key result
Epicardial preadipocytes secrete ~15-fold more PAPP-A than subcutaneous cells, restoring IGF-I signaling in human cardiomyocytes.
Why the study?
Little is known about the cellular biology of fat surrounding the human heart, motivating an investigation into whether epicardial fat cells differentially express bioactive molecules that can affect cardiac function.
Effect estimate: 15-fold higher
p-value: p=< 0.0001
Human epicardial fat cells differentially express high levels of PAPP-A, which can regulate IGF-I signaling in cardiomyocytes.
Hypothesis-generating for epicardial fat-IGF-I signaling; should not yet change practice or guide human studies.
Little is known about the cellular biology of fat surrounding the human heart. In this study, we obtained paired samples of epicardial fat, the visceral fat depot attached to the heart, and subcutaneous skin fat from patients undergoing open heart surgery to test the hypothesis that human epicardial fat cells differentially express bioactive molecules that have the potential to affect cardiac function. First, we characterized the free fatty acids (FFAs), adipocytokines, and growth factors secreted by isolated adipocytes and preadipocytes in cell culture. There was little to distinguish the fat cell secretory products in terms of FFAs and adipocytokines. The most striking finding was that preadipocytes from epicardial adipose tissue expressed high levels of pregnancy-associated plasma protein-A (PAPP-A), a novel metalloproteinase that enhances local insulin-like growth factor (IGF) action through cleavage of inhibitory IGF binding protein-4 (IGFBP-4). PAPP-A levels were 15-fold higher in conditioned medium from epicardial preadipocytes than from subcutaneous preadipocytes (P < 0.0001). PAPP-A was not expressed in mature adipocytes. Next we determined whether PAPP-A could affect IGF-I signaling in a human cardiomyocyte cell line. IGF-I activated receptor-mediated auto-phosphorylation, and this was blocked by wild-type and protease-resistant IGFBP-4. Addition of PAPP-A induced cleavage of wild-type, but not protease-resistant, IGFBP-4 thereby restoring IGF-I action. A proteolytically defective PAPP-A had no effect. IGF-I receptor-mediated signaling through the phosphatidylinositol 3-kinase pathway was similarly inhibited by IGFBP-4 and restored by PAPP-A. Thus, human epicardial fat cells differentially express PAPP-A, which has the potential to affect IGF signaling in the heart.
No takes yet. Share an insight, caveat, or question.
Conover et al. (2019) studied Patients undergoing open heart surgery. Epicardial adipose tissue vs. Subcutaneous skin fat was evaluated on PAPP-A levels in conditioned medium from preadipocytes (15-fold higher, p=< 0.0001). Epicardial preadipocytes secreted 15-fold higher levels of PAPP-A than subcutaneous preadipocytes (P < 0.0001), which cleaved IGFBP-4 and restored IGF-I signaling in human cardiomyocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: